Literature DB >> 22992811

A disease severity scoring system for children with type 1 Gaucher disease.

Staci Kallish1, Paige Kaplan.   

Abstract

UNLABELLED: Almost half of patients with Gaucher disease are diagnosed by the age of 10 years, and approximately two thirds are diagnosed by the age of 20 years. Besides symptomatic children, some presymptomatic children are being diagnosed through community screening programs and because of affected siblings. In addition, it is anticipated that in the near future, newborn screening for lysosomal diseases such as Gaucher disease will be introduced in the USA, identifying additional pre/nonsymptomatic children. Currently, there is no severity scoring system for children. A validated disease severity scoring system in the pediatric Gaucher population will be essential for classifying disease severity in these children, monitoring their disease progression, making decisions about when to treat them, and monitoring disease improvement with therapy. A severity scoring system will also be helpful in comparing therapeutic options as new therapies are designed. Therefore, a Pediatric Gaucher Severity Scoring System (PGS3) was devised using expert opinion and validated in 26 patients with type 1 Gaucher disease. The PGS3 correlates well with disease severity in patients at diagnosis and over time.
CONCLUSION: A practical system that will help clinical management, based on signs and symptoms in children with type 1 Gaucher disease, is presented.

Entities:  

Mesh:

Year:  2012        PMID: 22992811     DOI: 10.1007/s00431-012-1830-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease.

Authors:  J Charrow; H C Andersson; P Kaplan; E H Kolodny; P Mistry; G Pastores; B E Rosenbloom; C R Scott; R S Wappner; N J Weinreb; A Zimran
Journal:  Arch Intern Med       Date:  2000-10-09

2.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

3.  The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.

Authors:  Paige Kaplan; Hans C Andersson; Katherine A Kacena; John D Yee
Journal:  Arch Pediatr Adolesc Med       Date:  2006-06

4.  Disease severity in sibling pairs with type 1 Gaucher disease.

Authors:  Deborah Elstein; Ayelet Gellman; Gheona Altarescu; Aya Abrahamov; Irith Hadas-Halpern; Mici Phillips; Maya Margalit; Ehud Lebel; Menachem Itzchaki; Ari Zimran
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

5.  Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.

Authors:  R Kauli; R Zaizov; L Lazar; A Pertzelan; Z Laron; A Galatzer; M Phillip; Y Yaniv; I J Cohen
Journal:  Isr Med Assoc J       Date:  2000-02       Impact factor: 0.892

6.  Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

Authors:  P Kaplan; A Mazur; O Manor; J Charrow; J Esplin; T J Gribble; R S Wappner; J S Wisch; N J Weinreb
Journal:  J Pediatr       Date:  1996-07       Impact factor: 4.406

7.  A validated disease severity scoring system for adults with type 1 Gaucher disease.

Authors:  Neal J Weinreb; Maria D Cappellini; Timothy M Cox; Edward H Giannini; Gregory A Grabowski; Wuh-Liang Hwu; Henry Mankin; Ana Maria Martins; Carolyn Sawyer; Stephan vom Dahl; Michael S Yeh; Ari Zimran
Journal:  Genet Med       Date:  2010-01       Impact factor: 8.822

Review 8.  Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.

Authors:  S Zevin; A Abrahamov; I Hadas-Halpern; R Kannai; E Levy-Lahad; M Horowitz; A Zimran
Journal:  Q J Med       Date:  1993-09

9.  A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.

Authors:  Maja Di Rocco; Fiorina Giona; Francesca Carubbi; Silvia Linari; Fabrizio Minichilli; Roscoe O Brady; Giuliano Mariani; Maria Domenica Cappellini
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

10.  Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease.

Authors:  M Maas; T Hangartner; G Mariani; K McHugh; S Moore; G A Grabowski; P Kaplan; A Vellodi; J Yee; L Steinbach
Journal:  Skeletal Radiol       Date:  2008-03       Impact factor: 2.199

View more
  5 in total

1.  Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening.

Authors:  Amy C Yang; Louise Bier; Jessica R Overbey; Jessica Cohen-Pfeffer; Khyati Desai; Robert J Desnick; Manisha Balwani
Journal:  Genet Med       Date:  2016-10-13       Impact factor: 8.822

2.  Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.

Authors:  Richard Sam; Emory Ryan; Emily Daykin; Ellen Sidransky
Journal:  Expert Opin Pharmacother       Date:  2021-03-25       Impact factor: 4.103

3.  Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.

Authors:  Marcio Andrade-Campos; Pilar Alfonso; Pilar Irun; Judith Armstrong; Carmen Calvo; Jaime Dalmau; Maria-Rosario Domingo; Jose-Luis Barbera; Horacio Cano; Maria-Angeles Fernandez-Galán; Rafael Franco; Inmaculada Gracia; Miguel Gracia-Antequera; Angela Ibañez; Francisco Lendinez; Marcos Madruga; Elena Martin-Hernández; Maria Del Mar O'Callaghan; Alberto Pérez Del Soto; Yolanda Ruiz Del Prado; Ignacio Sancho-Val; Pablo Sanjurjo; Miguel Pocovi; Pilar Giraldo
Journal:  Orphanet J Rare Dis       Date:  2017-05-03       Impact factor: 4.123

Review 4.  Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement.

Authors:  Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu
Journal:  Insights Imaging       Date:  2019-07-10

5.  The N370S/R496H genotype in type 1 Gaucher disease - Natural history and implications for pre symptomatic diagnosis and counseling.

Authors:  Natasha Zeid; Chanan Stauffer; Amy Yang; Hetanshi Naik; Luca Fierro; Jaya Ganesh; Manisha Balwani
Journal:  Mol Genet Metab Rep       Date:  2020-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.